Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks News

Nalak Das headshot

An Outstanding Week for Market Amid Record Job Losses: 5 Picks

Market's worst is behind us as negative estimates are already factored in valuations.

Sanghamitra Saha headshot

6 ETF Areas Beating S&P 500 in 2020

The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.

Zacks Equity Research

Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates

Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

Zacks Equity Research

Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 5.41% and -53.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Biotech ETFs Poised to Benefit From Coronavirus

Rising investor interest in coronavirus related stocks will benefit these ETFs

Zacks Equity Research

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

Zacks Equity Research

Coronavirus Vaccine Efforts to Aid Moderna (MRNA) Q1 Earnings?

Moderna (MRNA) is progressing with coronavirus vaccine development. While grants for development are expected to have aided revenues, increased clinical activity is expected to have increased expenses.

Zacks Equity Research

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Twilio and Wayfair

The Zacks Analyst Blog Highlights: Moderna, Twilio and Wayfair